Closely-held Interface Biologics (IBI) appointed Kelley Dealhoy to the position of VP business development.
Ms. Kelley has more than 25 years of experience in the life science sector, with the last 15 years dedicated to structuring, implementing and overseeing pharmaceutical partnerships.
Prior to joining IBI, Ms. Dealhoy was a life science advisor in Deloitte’s Financial Advisory (M&A) practice, where she worked with biotech and pharmaceutical companies to develop and implement strategies to drive growth and unlock value. She also has held leadership roles in R&D and business development at leading pharmaceutical companies, including Eli Lilly, Merck and Novartis.
“Her depth of experience in biotech/pharma is critical to our go-forward strategy and her interest in joining our organization underscores the strength of IBI’s value proposition,” IBI president and CEO, Tom Reeves, said in a statement.
Ms. Dealhoy said this is an exciting time at IBI as it expands into drug delivery with the potential to address debilitating conditions, such as posterior inflammatory eye diseases, including diabetic macular edema, retinal vein occlusion and non-infectious uveitis with the IBE-814 IVT implant.
